BioCryst Pharmaceuticals announced that Donald Fong, MD, MPH, has been appointed as the company’s new chief medical officer, effective immediately. Dr. Fong joined BioCryst in April 2024 as vice president of the ophthalmology therapeutic area.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reports inducement grants under Nasdaq listing rule
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BioCryst to Present at Upcoming Investor Conferences
- BioCryst price target raised to $16 from $15 at JMP Securities
- BioCryst price target raised to $7 from $6 at Barclays